Cellular association and cytotoxicity of anti-CD74-targeted lipid drug-carriers in B lymphoma cells

Journal of Controlled Release

Volumn 94, Issue 1, 2004, Pages 155-161

  Lundberg, Bo B ^a   Griffiths, Gary ^b   Hansen, Hans J ^b  

^a ÅBO AKADEMI UNIVERSITY   (Finland)

^b IMMUNOMEDICS INC   (United States)

Author keywords

5 Fluorodeoxyuridine; B cell lymphomas; Immunoconjugates; Lipid emulsions; Liposomes; Targeted drug delivery

Indexed keywords

ANTIGEN-ANTIBODY REACTIONS; CELLS; COMPLEXATION; CYTOLOGY; DRUG PRODUCTS; EMULSIONS; IMMUNOLOGY; LIPIDS; TOXICITY;

LIGANDS; THERAPEUTICS;

DRUG DOSAGE;

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; 3',5' O DIOLEOYLFLOXURIDINE; ANTIBODY LL1; ANTINEOPLASTIC AGENT; DRUG CARRIER; LIPOSOME; MACROGOL; PROTEIN ANTIBODY; UNCLASSIFIED DRUG;

ARTICLE; B CELL LYMPHOMA; CALCULATION; CONTROLLED STUDY; CYTOTOXICITY; DRUG DELIVERY SYSTEM; EMULSION; HUMAN; HUMAN CELL; IMMUNOREACTIVITY; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; T CELL LEUKEMIA; TARGET CELL;

EID: 0347996090     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jconrel.2003.09.016     Document Type: Article

References (31)

1. Bally M.B., Lim H., Cullis P.R., Mayer L.D. Controlling the drug delivery attributes of lipid-based drug formulations. J. Liposome Res. 8:1998;299-335.
2. Lundberg B. The solubilization of lipophilic derivatives of podophyllotoxins in sub-micron sized lipid emulsions and their cytotoxic activity against cancer cells in culture. Int. J. Pharm. 109:1994;73-81.
3. Lundberg B.B. A submicron lipid emulsion coated with amphipathic polyethylene glycol for parenteral administration of paclitaxel (taxol). J. Pharm. Pharmacol. 49:1997;16-21.
4. Lundberg B.B. Biologically active camptothecin derivatives for incorporation into liposome bilayers and lipid emulsions. Anti-Cancer Drug Des. 13:1998;453-461.
5. Gabizon A., Price D.C., Huberty J., Bresalier R.S., Papahadjopoulos D. Effect of lipid composition and other factors on the targeting of liposomes to experimental tumors: biodistribution and imaging studies. Cancer Res. 50:1990;6371-6378.
6. Allen T.M. Liposomes. Opportunities in drug delivery. Drugs. 54:1997;8-14.
7. Papahadjopoulos D., Kirpotin D.K., Park J.W., Hong K., Shao Y., Shalaby R., Colbert G., Benz C.C. Targeting of drugs to solid tumors using anti-HER2 immunoliposomes. J. Liposome Res. 8:1998;425-442.
8. Lopes de Menezes D.E., Pilarski L.M., Allen T.M. In vivo and in vitro targeting of immunoliposomal doxorubicin to human B-cell lymphoma. Cancer Res. 58:1998;3320-3330.
9. Moase E.H., Qi W., Ishida T., Gabos Z., Longenecker B.M., Zimmermann G.L., Ding L., Krantz M., Allen T.M. Anti-MUC-1 immunoliposomal doxorubicin in the treatment of murine models of metastatic breast cancer. Biochim. Biophys. Acta. 1510:2001;43-55.
10. Moreira J.N., Hansen C.B., Gaspar R., Allen T.M. A growth factor antagonist as a targeting agent for sterically stabilized liposomes in human small cell lung cancer. Biochim. Biophys. Acta. 1514:2001;303-317.
11. Jain R.K. Delivery of novel therapeutic agents in tumors: physiological barriers and strategies. J. Natl. Cancer Inst. 81:1989;570-576.
12. Lundberg B.B., Griffiths G., Hansen H.J. Conjugation of an anti-B-cell lymphoma monoclonal antibody, LL2, to long-circulating drug-carrier lipid emulsions. J. Pharm. Pharmacol. 51:1999;1099-1105.
13. Lundberg B.B., Griffiths G., Hansen H.J. Specific binding of sterically stabilized anti-B-cell immunoliposomes and cytotoxicity of entrapped doxorubicin. Int. J. Pharm. 205:2000;101-108.
14. Hansen H.J., Ong G.L., Diril H., Valdez A., Roche P.A., Griffiths G.L., Goldenberg D.M., Mattes M.J. Internalization and catabolism of radiolabelled antibodies to the MHC class-II invariant chain by B-cell lymphomas. Biochem. J. 320:1996;293-300.
15. Griffiths G.L., Govindan S.V., Sgouros G., Ong G.L., Goldenberg D.M., Mattes M.J. Cytotoxicity with Auger electron-emitting radionuclides delivered by antibodies. Int. J. Cancer. 81:1999;985-992.
16. 90Yttrium. Clin. Cancer Res. 7:2001;1505-1510.
17. Lundberg B. Preparation of drug-carrier emulsions stabilized with phosphatidylcholine-surfactant mixtures. J. Pharm. Sci. 83:1994;72-75.
18. Lundberg B.B., Mortimer B.C., Redgrave T.G. Submicron lipid emulsions containing amphipathic polyethylene glycol for use as drug-carriers with prolonged circulation time. Int. J. Pharm. 134:1996;119-127.
19. Straubinger R.M., Papahadjopoulos D., Hong K. Endocytosis and intracellular fate of liposomes using pyranine as a probe. Biochemistry. 29:1990;4929-4939.
20. Mosmann T., Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods. 65:1983;55-63.
21. Hansen C.B., Kao G.Y., Moase E.H., Zalipsky S., Allen T.M. Attachment of antibodies to sterically stabilized liposomes: evaluation, comparison and optimization of coupling procedures. Biochim. Biophys. Acta. 1239:1995;133-144.
22. Sapra P., Allen T.M. Internalizing antibodies are necessary for improved therapeutic efficacy of antibody-targeted liposomal drugs. Cancer Res. 62:2002;7190-7194.
23. Allen T.M., Sapra P., Moase E., Moreira J., Iden D. Adventures in targeting. J. Liposome Res. 12:2002;5-12.
24. Kirpotin D., Park J.W., Hong K., Zalipsky S., Li W.-L., Carter P., Benz C.C., Papahadjopoulos D. Sterically stabilized anti-HER2 immunoliposomes: design and targeting to human breast cancer cells in vitro. Biochemistry. 36:1997;66-75.
25. Lopes de Menezes D.E., Kierchmeier M.J., Gagne J.-F., Pilarski L.M., Allen T.M. Cellular trafficking and cytotoxicity of anti-CD19-targeted liposomal doxorubicin in B lymphoma cells. J. Liposome Res. 9:1999;199-228.
26. Koning G.A., Morselt H.W.M., Velinova M.J., Donga J., Gorter A., Allen T.M., Zalipsky S., Kamps J.A.A.M., Scherphof G.L. Selective transfer of a lipophilic prodrug of 5-fluorodeoxyuridine from immunoliposomes to colon cancer cells. Biochim. Biophys. Acta. 1420:1999;153-167.
27. Constantinides P.P., Lambert K.J., Tustian A.K., Schneider B., Lalji S., Ma W., Wentzel B., Kessler D., Worah D., Quay S.C. Formulation development and antitumor activity of a filter-sterilizable emulsion of paclitaxel. Pharm. Res. 17:2000;175-182.
28. Perkins W.R., Ahmad I., Li X., Hirsh D.J., Masters G.R., Fecko C.J., Lee J., Ali S., Nguyen J., Schupsky J., Herbert C., Janoff A.S., Mayhew E. Novel therapeutic nano-particles (lipocores): trapping poorly water soluble compounds. Int. J. Pharm. 200:2000;27-39.
29. Bom D., Curran D.P., Zhang J., Zimmer S.G., Bevins R., Kruszewski S., Howe J.N., Bingcang A., Latus L.J., Burke T.G. The highly lipophilic DNA topoisomerase I inhibitor DB-67 displays elevated lactone levels in human blood and potent anticancer activity. J. Control. Release. 74:2001;325-333.
30. Maranhao R.C., Graziani S.R., Yamaguchi N., Melo R.F., Latrilha M.C., Rodrigues D.G., Couto R.D., Schreier S., Buzaid A.C. Association of carmustine with a lipid emulsion: in vitro, in vivo and preliminary studies in cancer patients. Cancer Chemother. Pharmacol. 49:2002;487-498.
31. Shih L., Ong G.L., Burton J., Mishina D., Goldenberg D.M., Mattes M.J. Localization of an antibody to CD74 (MHC class II invariant chain) to human B cell lymphoma xenografts in nude mice. Cancer Immunol. Immunother. 49:2000;208-216.